Oncolytics Biotech reported that its pelareorep‑based combination therapy achieved a 19.5‑month median duration of response in patients with second‑line KRAS‑mutant microsatellite‑stable metastatic colorectal cancer, a result that far exceeds the 4‑6‑month benchmark historically observed with standard care.
The study, designated REO 022, also showed a 33 % objective response rate, tripling the 6‑11 % rate seen with conventional therapy. The durability and response magnitude suggest a meaningful therapeutic advantage in a population with limited options.
The company’s CEO, Jared Kelly, said, "We believe these data demonstrate a compelling durability signal for pelareorep in colorectal cancer. A 19.5‑month median duration of response in second‑line patients—representing a three‑ to four‑fold improvement over historical expectations—highlights pelareorep's potential to deliver sustained benefit in a population with few effective options. We believe these results support a path toward accelerated approval in second‑line RAS‑mutant MSS metastatic colorectal cancer, and we are actively engaging with the FDA to align on a regulatory strategy leveraging our ongoing randomized study."
Oncolytics is actively pursuing an accelerated approval pathway, having received Fast Track designation for the pelareorep plus bevacizumab/FOLFIRI combination in February 2026. The company is also enrolling patients in a randomized Phase 2 study (REO‑033) in the same patient population, positioning it to further validate the clinical benefit and support regulatory submissions.
As a clinical‑stage biotechnology company, Oncolytics continues to incur significant research and development expenses and reports net losses, with cash runway extending through 2026. The positive clinical data strengthen the company’s pipeline and may enhance its attractiveness to potential partners or investors, while the ongoing financial profile underscores the importance of continued funding to support future development milestones.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.